⚡ Quick Start — If You Read Nothing Else

The 10 most important things to know right now about protecting your bones.

Osteoporosis is common and one of the most treatable conditions of aging. It thins and weakens bone so it breaks more easily. The harm comes almost entirely from fractures — especially of the hip and spine. Good treatment prevents most of those fractures.
A broken bone from a minor fall is a warning, not just bad luck. A “fragility fracture” (a break from a fall from standing height or less) means you are at very high risk of another fracture — often within the next 1–2 years. That alone can justify treatment, even if a bone-density scan is not in the “osteoporosis” range.
A simple, painless scan finds high risk early. A DXA bone-density scan gives a “T-score,” and the FRAX calculator estimates your 10-year chance of fracture. Together they let your doctor treat before the first break.
Two families of medicine, and the order can matter. Some medicines slow bone loss (bisphosphonates, denosumab). Others build new bone (teriparatide, abaloparatide, romosozumab). For people at very high risk, starting with a bone-builder and then following with a bone-preserver builds more bone and prevents more fractures than the reverse.
Never simply stop denosumab (Prolia). It does not stay in your bones. If it is stopped or even delayed without a follow-on medicine, bone can be lost rapidly and you can suffer multiple spine fractures. This is the single most important safety rule in this guide.
Every bone-building course must be followed by a bone-preserving medicine. The new bone you grow with teriparatide, abaloparatide, or romosozumab is quickly lost if it is not “locked in” afterward with a bisphosphonate or denosumab.
“Drug holidays” apply to bisphosphonates — not to every medicine. Because bisphosphonates linger in bone, some people can pause them after 3–5 years. Denosumab and the bone-builders cannot be paused that way.
The scary side effects are real but rare. Jaw problems (osteonecrosis) and unusual thigh-bone fractures happen, but for people at genuine fracture risk the fractures prevented vastly outnumber them. The FDA also removed the old bone-cancer warning from the bone-builders after long-term data were reassuring.
The foundation is for everyone. Enough calcium (mostly from food) and vitamin D, weight-bearing and muscle-strengthening exercise, not smoking, limiting alcohol, and preventing falls. These support every treatment plan — but for people who need medicine, they are not enough on their own.
This guide does not replace your medical team. It helps you ask better questions and partner in decisions. Your plan should be individualized to your risk, your other conditions, and your preferences.

▼ Collapse

How to use this guide. Use the tabs to move through stages: Start Here, Bone-Density Tests & Risk, Calcium, Vitamin D & Exercise, Bone Medicines, Treatment Length & Drug Holidays, Falls & Living Well, and Support & Resources. Every stage has a Questions to Ask Your Doctor box and caregiver notes. A plain-language Glossary is in the last tab.

Start Here: Understanding Osteoporosis

Bone is living tissue. All through life your body removes a little old bone and lays down a little new bone, a constant remodeling that keeps the skeleton strong. Osteoporosis (“porous bone”) is what happens when removal outpaces rebuilding: bones lose density and their internal scaffolding thins, so they break more easily — sometimes from a minor stumble, a bump, or even, in the spine, no obvious injury at all.

Osteoporosis itself causes no symptoms. You cannot feel your bones thinning. That is why it is often called a “silent” disease — and why, for too many people, the first sign is a broken bone. The good news, and the central message of this guide, is that this is no longer something we can only treat after the damage is done. We can find high risk early with a simple scan and a risk calculator, and we have medicines that cut the risk of the most serious fractures dramatically.

Why fractures are the whole story. Osteoporosis matters because of what it leads to: broken bones. Hip and spine fractures in particular can cause lasting pain, loss of height and independence, and — for hip fractures in older adults — a serious risk to health and life in the year that follows. Preventing these fractures is the entire goal of treatment.

How common is it?

Osteoporosis is one of the most common chronic conditions of aging. Worldwide, an estimated half a billion people are affected. Roughly one in three women and one in five men over the age of 50 will break a bone because of osteoporosis at some point. It is not a normal, untreatable part of getting older — it is a recognized medical condition with effective treatments.

It affects men too — and is badly under-treated in them

Although osteoporosis is more common in women after menopause, men get it as well, and a man who breaks a hip is more likely than a woman to have serious complications. Yet men are far less often tested and treated. If you are a man over 70, or a man of any age who has broken a bone easily, take low hormone (testosterone), or use long-term steroids, ask specifically about bone-density testing.

Low bone mass (osteopenia): Bone density is below average but not yet in the osteoporosis range (T-score between −1.0 and −2.5). Many people here do well with foundation care; some at higher risk benefit from medicine.
Osteoporosis by density: A T-score at or below −2.5.
Clinical osteoporosis (by fracture): A fragility fracture of the hip or spine — or, often, of the wrist, upper arm, or pelvis — means you have osteoporosis regardless of your T-score, and you should usually be treated.
Very high risk: For example, a recent fracture, multiple fractures, a very low T-score, fractures while already on treatment, or high steroid doses. People here are often best served by starting with a bone-building medicine.

Some risks you cannot change (older age, female sex, family history, having already broken a bone, certain ethnic backgrounds, a slender frame). Many you can influence or treat:

Hormones: the drop in estrogen after menopause; low testosterone in men.
Medicines: especially long-term oral steroids (such as prednisone), and some others your doctor can review.
Other conditions (“secondary causes”): an overactive thyroid or parathyroid gland, celiac disease and other causes of poor absorption, inflammatory and rheumatologic diseases, certain blood and kidney disorders, and more. Finding and treating these is part of good osteoporosis care.
Lifestyle: smoking, heavy alcohol use, very low body weight, too little calcium or vitamin D, and physical inactivity.

A realistic, hopeful frame. Osteoporosis is controlled, not cured — like high blood pressure. But the fractures it causes are largely preventable. With the right plan, the great majority of people stay upright, independent, and active.

Based on my history, am I at risk for osteoporosis or a fracture? Should I have a bone-density scan?
Have I had any fracture as an adult that might count as a “fragility fracture”?
Could another condition or medicine be weakening my bones? Should I be checked for secondary causes?
Is my osteoporosis (if I have it) the kind that needs medicine, or can I start with foundation care?
What is my personal goal of treatment — which fractures are we trying to prevent?

This guide is educational and does not replace personalized medical advice. Always discuss your own situation with a qualified clinician before making decisions.

Bone-Density Tests & Fracture Risk: What the Numbers Mean

Two tools work together to tell you where you stand: a bone-density scan (DXA) and a fracture-risk calculator (FRAX). Understanding both helps you and your doctor decide whether you need medicine and which one.

The DXA scan and your T-score

DXA (dual-energy X-ray absorptiometry) is a quick, painless, low-radiation scan — usually of your hip and lower spine — that measures how dense your bones are. The main result is the T-score, which compares your bone density to that of a healthy young adult:

−1.0 or higher: normal bone density.
Between −1.0 and −2.5: low bone mass (osteopenia).
−2.5 or lower: osteoporosis.

(You may also see a “Z-score,” which compares you to others your own age and is used mainly in younger people and to flag secondary causes.)

A key point most people miss. The T-score is only part of the picture. You can have a fracture that defines osteoporosis even when your T-score is in the “osteopenia” range — and FRAX may show high risk at a T-score that, by itself, would not have triggered treatment. The decision is about your overall risk, not one number.

FRAX: your 10-year fracture risk

FRAX is a free online calculator (from the University of Sheffield) that estimates your chance of a major fracture over the next 10 years. It combines your age, sex, weight and height, prior fracture, family history, smoking, alcohol, steroid use, rheumatoid arthritis, and other secondary causes — with or without your hip bone-density value. Because it is calibrated to each country’s own fracture and death rates, the same risk factors can give different numbers (and different treatment thresholds) in different countries.

Trabecular bone score (TBS): a measure of bone quality (the texture of the internal scaffolding) calculated from the same spine DXA image. It can refine your FRAX risk when available.
Vertebral fracture assessment (VFA): a low-dose image of the spine, often done at the same visit, that can detect spine fractures you never knew you had — because many spine fractures cause no symptoms. Finding one changes you to “clinical osteoporosis” and usually means treatment.

Who should be tested?

General guidance (your doctor will personalize it) suggests bone-density testing for:

All women 65 and older.
Younger postmenopausal women with risk factors (such as low body weight, prior fracture, family history, smoking, or steroid use).
Men 70 and older — and younger men with risk factors.
Anyone over 50 who breaks a bone from a minor fall.
People on long-term steroids or with conditions known to weaken bone.

Looking for a hidden cause (“secondary” osteoporosis)

Especially if your bone loss is severe, unexpected for your age, or keeps getting worse on treatment, your doctor may order blood and urine tests to check for treatable causes — for example vitamin D level, calcium, kidney and thyroid function, parathyroid hormone, and (in men) testosterone, plus screening for celiac disease or other conditions when appropriate. Treating a hidden cause is part of the plan, not a detour from it.

What is my T-score, and at which sites (hip, spine)? Do I have osteopenia or osteoporosis?
What is my FRAX 10-year risk of a major fracture and of a hip fracture? Is that high enough to treat?
I had a fracture — does that mean I should be treated even if my T-score isn’t in the osteoporosis range?
Should I have a VFA or spine images to check for fractures I might not know about?
Do I need blood or urine tests to look for a hidden cause of bone loss?
How often should my DXA be repeated, and what change would be meaningful?

Caregiver note. Bring a list of every fracture the person has had as an adult — even a wrist or rib from “just a fall” — and a current medication list (especially steroids). These details strongly influence the risk assessment and are easy to forget in the moment.

The Foundation for Everyone: Calcium, Vitamin D, Nutrition & Exercise

Whether or not you take medicine, these basics support your bones and your safety. Be clear-eyed, though: for people who genuinely need medication, supplements and exercise are support, not a substitute. They have not been shown to prevent fractures on their own in people at high risk.

Calcium — mostly from food

Most adults do well with roughly 1,000–1,200 mg of calcium per day, ideally from food. Good sources include dairy (milk, yogurt, cheese), fortified plant milks and juices, tofu set with calcium, canned fish with soft bones (sardines, salmon), and leafy greens. If your diet falls short, a modest supplement can fill the gap — but more is not better, and very high supplement doses are not recommended.

Why “food first.” Getting calcium from food spreads it through the day and avoids the concerns sometimes raised about large supplement doses. Aim to cover most of your needs at the table, and supplement only the shortfall.

Vitamin D — the partner nutrient

Vitamin D helps your body absorb calcium and supports muscle function (which helps prevent falls). Many older adults are low. A common target is to keep your blood level adequate with a daily supplement; your doctor may check a level and adjust the dose, repleting more aggressively if you are deficient. Correcting low vitamin D and calcium is especially important before starting the stronger bone medicines, because those medicines can lower blood calcium.

Protein and overall nutrition

Adequate protein supports both bone and muscle, particularly in older adults and after a fracture. A balanced diet with enough calories, protein, fruits, and vegetables benefits the whole skeleton.

Exercise: build strength and balance

Two kinds of exercise matter most:

Weight-bearing activity (walking, stair-climbing, dancing) signals bone to stay strong.
Muscle-strengthening / resistance training (bands, weights, body-weight exercises) builds the muscle that protects bone and improves balance.
Balance work (such as tai chi or targeted programs) reduces falls — and most fractures happen because of a fall.

If you already have a spine fracture or severe osteoporosis, ask a physical therapist about safe technique. In general, avoid heavy forward-bending and twisting movements (like deep sit-ups or toe-touches with weight) that can stress the spine. A professional can tailor a program that is both safe and effective.

Don’t smoke; go easy on alcohol

Smoking weakens bone and is one of the most worthwhile things to change — the Utah Tobacco Quit Line (1-800-QUIT-NOW) is free. Keep alcohol moderate (no more than 1–2 standard drinks a day), since heavier use harms bone and raises fall risk.

How much calcium am I getting from food, and do I actually need a supplement — and if so, how much?
Should my vitamin D level be checked? What dose should I take?
What specific exercises are safe and helpful for me, given my bone density and any fractures?
Should I see a physical therapist for a strength-and-balance program?
Are any of my supplements or habits working against my bones?

Caregiver note. Help make the basics routine: a calcium-rich food at each meal, the vitamin D supplement in the same spot as the morning pills, and a regular, realistic walk or class. Encouragement matters — this is long-term, often invisible work.

Bone Medicines: Slowing Loss and Building New Bone

There are two big families. Understanding the difference is the key to understanding your whole treatment plan.

The core idea in one sentence. Some medicines slow the loss of bone (antiresorptives: bisphosphonates and denosumab); others build new bone (anabolics: teriparatide, abaloparatide, romosozumab) — and for people at very high risk, building first and then preserving works best.

Family 1: Medicines that slow bone loss (antiresorptives)

Bisphosphonates — usually the first choice

These are the global mainstay: effective, inexpensive, and well studied over decades. They reduce fractures of the spine and hip and stay in bone for a long time (which is what makes “drug holidays” possible later).

Alendronate (Fosamax) — a weekly pill.
Risedronate (Actonel, Atelvia) — a weekly or monthly pill.
Ibandronate (Boniva) — a monthly pill or an injection every 3 months (mainly helps the spine).
Zoledronic acid (Reclast) — a once-a-year intravenous (IV) infusion; a strong option if pills are hard to take or absorb.

Taking oral bisphosphonates correctly matters a lot. Take the pill first thing in the morning on an empty stomach, with a full glass of plain water (not coffee, juice, or mineral water), and then stay sitting or standing upright — do not lie down — and eat or drink nothing else for 30–60 minutes. This protects the esophagus and lets the medicine absorb. The yearly IV infusion avoids these steps entirely.

Denosumab (Prolia) — a twice-yearly injection

Denosumab is a powerful antiresorptive given as a shot under the skin every 6 months. It strongly slows bone loss and reduces spine, hip, and other fractures, and it can be used even when kidney function is reduced (with care). Lower-cost biosimilar versions (such as Jubbonti) are now available.

Bone Health During Pregnancy & Breastfeeding

Pregnancy and breastfeeding place significant demands on the skeleton. For most people this is manageable with adequate calcium and vitamin D, and any bone density changes reverse after weaning. However, some people develop pregnancy-related bone complications that require medical attention.

Normal bone changes in pregnancy

Your baby needs calcium for its growing skeleton. Most of this comes from intestinal calcium absorption (which increases during pregnancy), not from your bones.
Bone density may decline slightly during breastfeeding as calcium is transferred to breast milk; this typically reverses within 6-12 months of weaning.
Adequate daily calcium (1,000-1,200 mg) and vitamin D (600-800 IU; higher doses may be recommended if deficient) support bone health throughout pregnancy and breastfeeding.

Pregnancy-associated osteoporosis (PAO)

Rarely, people develop severe bone loss during or after pregnancy, leading to vertebral fractures or hip fractures. This condition is called pregnancy-associated osteoporosis (PAO). Symptoms include back pain, loss of height, or difficulty moving. If you develop severe back pain during or after pregnancy, contact your healthcare provider; a DEXA scan and spine imaging may be needed.

Transient osteoporosis of the hip

A specific condition where hip pain develops in late pregnancy or the early postpartum period due to temporary bone loss in the hip. It typically resolves on its own after delivery. Rest, limited weight-bearing, and pain management are the usual approach. Alert your doctor to any new hip pain that starts during pregnancy.

Osteoporosis medications during pregnancy and breastfeeding

Most osteoporosis medications should not be used during pregnancy or breastfeeding. Discuss any planned pregnancy with your rheumatologist or endocrinologist well in advance.

Bisphosphonates (alendronate, risedronate, zoledronic acid) — stored in bone for years and may cross the placenta; avoid during pregnancy and breastfeeding. If you are considering pregnancy, discuss a drug holiday with your doctor. Animal data show fetal harm with high doses.
Denosumab (Prolia) — contraindicated in pregnancy; animal studies show increased fetal bone effects and stillbirth. Women of childbearing age must use effective contraception during and for at least 5 months after the last dose. Do not breastfeed during therapy.
Teriparatide (Forteo) — animal data show bone tumors at high doses; contraindicated in pregnancy. Avoid breastfeeding.
Romosozumab (Evenity) — limited data; avoid in pregnancy.
Calcium and vitamin D — safe and recommended during pregnancy and breastfeeding. Do not stop these supplements.

Planning a pregnancy while on osteoporosis treatment: tell your specialist early. For bisphosphonates, your doctor may recommend stopping treatment and monitoring bone density for several months before conceiving, though the optimal timing varies by drug and your individual fracture risk.

⚠ The most important safety rule in this guide. Denosumab does not stay in your bones. If it is stopped — or even just delayed past the 6-month mark — without switching to another medicine, bone can be lost rapidly and you can suffer multiple spine fractures within months. If you ever plan to stop denosumab, or might miss a dose for any reason (cost, a move, surgery, a dental procedure, hospitalization), your doctor must arrange a follow-on medicine, almost always a bisphosphonate. Never just stop.

Family 2: Medicines that build new bone (anabolics)

These are the most powerful tools for people at very high risk — for example, after a serious fracture, with very low bone density, or when fractures keep happening on other treatment. They are given for a limited course and must always be followed by a bone-preserving medicine to keep the gains.

Teriparatide (Forteo, and biosimilars) — a daily self-injection; a lab-made form of part of the parathyroid hormone that tells bone to grow.
Abaloparatide (Tymlos) — a daily self-injection in the same family; approved for postmenopausal women and for men.
Romosozumab (Evenity) — a monthly set of injections (two shots) given for up to 12 months; it both builds bone and slows its loss.

⚠ Romosozumab and the heart. Romosozumab carries a boxed warning about a possible increase in heart attack and stroke. It should not be started within a year of a heart attack or stroke, and your doctor will weigh your heart risk before using it.

Good news on an old worry. Teriparatide and abaloparatide once carried a warning about a rare bone cancer (osteosarcoma) seen only in rats, plus a 2-year lifetime limit. After years of real-world data found no such signal in people, the FDA removed both the boxed warning and the strict lifetime limit. Your doctor will still individualize how long you use them.

Hormone-related options

Raloxifene (Evista) — a daily pill (a “SERM”) that reduces spine fractures and also lowers the risk of one type of breast cancer, but slightly raises the risk of blood clots and does not reduce hip fractures. An option for some, especially younger postmenopausal women.
Menopausal hormone therapy (estrogen) — can help bone in selected younger postmenopausal women, with other benefits and risks to weigh individually.

Why order matters: sequencing

Build first, then preserve. For very-high-risk patients, starting with a bone-builder and then following with a bone-preserver builds more bone and prevents more fractures than starting with a standard medicine. There is a catch in the other direction: if you have already been on a strong bone-slowing medicine for a long time, a bone-builder may work a little less well afterward. This is exactly why sequencing is now a deliberate strategy your doctor plans from the start.

In broad strokes (your doctor will tailor this):

High risk: usually a bisphosphonate first (a pill, or the yearly infusion), or denosumab.
Very high risk (recent or multiple fractures, very low T-score, fractures on treatment): often an anabolic (bone-builder) first — romosozumab, teriparatide, or abaloparatide — then a bone-preserver.
Kidney problems: in mild-to-moderate kidney disease, denosumab is often preferred over bisphosphonates (which need adequate kidney function), with careful attention to blood calcium. In advanced kidney disease — especially people on dialysis — denosumab carries an FDA "boxed warning" (its strongest warning, added January 2024) for a risk of dangerously low blood calcium (severe hypocalcemia), so it should only be used in that setting under a specialist's care with close calcium monitoring.
Recent heart attack or stroke: romosozumab is avoided.
Cost and convenience: bisphosphonates are inexpensive; the bone-builders are costly and may need insurance approval.

Two rare but serious effects worry people most:

Osteonecrosis of the jaw (ONJ): an area of jaw bone that does not heal, usually after a tooth extraction or other dental surgery. It is rare in people taking these medicines for osteoporosis (far more common at the much higher cancer doses). Good dental health and telling your dentist you take these medicines lowers the risk further.
Atypical femoral fracture (AFF): an unusual crack or break in the thigh bone, sometimes preceded by new, dull thigh or groin pain. Also rare, and the risk relates to very long continuous use — one reason drug holidays exist for bisphosphonates.

The perspective that matters: for a person at genuine fracture risk, the hip and spine fractures these medicines prevent vastly outnumber these rare complications. Report new thigh or groin pain, or a jaw problem that won’t heal, promptly — but don’t let fear of the rare keep you from preventing the common.

Which medicine do you recommend for me, and why — a bisphosphonate pill or infusion, denosumab, or a bone-builder?
What’s the difference, for me, between a medicine that slows bone loss and one that builds new bone?
Am I “very high risk”? If so, should I start with a bone-building medicine?
If I start denosumab, what is the exact plan to make sure I never stop it without a follow-on medicine?
If I start a bone-builder, what medicine will follow it, and when?
Given my heart history, is romosozumab safe for me?
What are the real risks of jaw and thigh-bone problems for me, compared with the fractures we’re preventing?
Do I need a dental check-up before starting?

Caregiver note. Your role differs by medicine: with oral bisphosphonates, help with the empty-stomach, upright, full-glass-of-water routine; with denosumab, guard the calendar so doses are never late and a follow-on is always arranged before stopping; with daily anabolic injections, support the routine and proper technique. Watch for new thigh/groin pain or a non-healing jaw sore and report them.

How Long to Treat, Drug Holidays, and Safe Switching

Osteoporosis is a long-term condition, but that does not mean every medicine is taken forever. The plan is individual and is reviewed over time. Here is how the different medicines differ.

Bisphosphonates: reassess after 3–5 years

Because bisphosphonates linger in bone after you stop, many people can take a planned drug holiday after about 3–5 years (often 3 years for the yearly infusion, 5 years for pills). During a holiday, the bone benefit fades slowly, and pausing lowers the small risk of the rare thigh-bone and jaw problems. Your doctor reassesses your risk periodically and restarts treatment if it climbs again.

Who usually should not take a holiday. People still at high risk — for example, those with a very low T-score, a fracture during treatment, or a recent fracture — generally keep treating rather than pausing. A “holiday” is a planned medical decision, not simply stopping.

Denosumab: no holiday — always a planned next step

⚠ Denosumab cannot be “paused.” Because it does not stay in bone, stopping it leaves bone unprotected and can trigger rapid loss and multiple spine fractures. If denosumab is ever stopped, it must be followed by a bisphosphonate, on a schedule your doctor sets (typically beginning around the time the next denosumab dose would have been due). This is not optional.

Bone-builders: a limited course, then lock it in

Teriparatide, abaloparatide, and romosozumab are given for a limited time (commonly up to ~2 years for the daily injections, up to 12 months for romosozumab). The new bone you build is quickly lost if not followed by a bone-preserving medicine — so a bisphosphonate or denosumab always comes next. This “build, then preserve” hand-off is the whole point of using a bone-builder.

Switching medicines

People often move between medicines over the years — for example, from a bone-builder to a bone-preserver, or from one antiresorptive to another. There’s an order that works best (build before preserve), and some sequences blunt the next medicine’s effect, which is why these moves are planned, not improvised.

Because osteoporosis is silent, it’s easy to drift off treatment — many people stop oral bisphosphonates within a year. But the protection only works while you’re actually treated. If a medicine is hard to take, costs too much, or worries you, tell your doctor: there is almost always an alternative (a different schedule, the yearly infusion, an injection, a biosimilar, or patient-assistance help). Switching is far better than silently stopping.

How long should I take this medicine, and what happens next?
Am I a candidate for a bisphosphonate drug holiday — or am I too high-risk to pause?
If I’m on denosumab, what exactly is the plan so I never stop it unprotected?
After my bone-building course ends, which medicine will lock in the gains, and when does it start?
How will we decide whether treatment is working — repeat DXA, bone markers, or both?
What would make us restart, switch, or stop?

Caregiver note. Keep a simple treatment timeline: what medicine, started when, planned end date, and the next step. For denosumab, mark the dose dates and set reminders well in advance. If a holiday is planned, note when the next risk review is due so it isn’t forgotten.

Preventing Falls & Living Strong

Most fractures happen because of a fall. Strengthening bone is half the job; the other half is not falling in the first place. Fall prevention has many small parts that add up.

Make your home safer

Remove or secure loose rugs, cords, and clutter from walking paths.
Improve lighting, especially on stairs, in hallways, and on the route to the bathroom at night.
Add grab bars in the bathroom (by the toilet and in the shower/tub) and a non-slip mat.
Use sturdy handrails on stairs; consider a raised toilet seat or shower chair if needed.
Keep frequently used items within easy reach to avoid stretching or step stools.

Address the body

Vision: get eyes checked and update glasses; treat cataracts when appropriate.
Footwear: wear supportive, non-slip shoes — not loose slippers or socks alone.
Medications: ask your doctor or pharmacist to review anything that causes drowsiness, dizziness, or low blood pressure (some sleep aids, sedatives, and blood-pressure medicines).
Strength and balance: keep up resistance and balance exercise — it directly lowers fall risk.
Blood pressure & inner ear: report dizziness on standing or spinning sensations.

After a fracture, momentum matters. A recent fracture is the strongest predictor of the next one, and risk is highest in the first 1–2 years. This is exactly when treatment helps most — so secondary fracture prevention (treating osteoporosis right after a break) is a priority, not something to put off.

Living well with osteoporosis

A diagnosis does not mean wrapping yourself in cotton wool. Stay active within safe limits, keep social and engaged, and protect your independence. If you have spine fractures and chronic back pain, ask about physical therapy, posture and movement training, and pain management; bracing helps some people short-term. Many people live full, active lives for decades after diagnosis.

New thigh or groin pain (could signal a stress reaction before an atypical thigh-bone fracture) — especially if you’ve been on a bisphosphonate or denosumab a long time.
A non-healing sore, pain, or exposed bone in the mouth/jaw, particularly after dental work.
Sudden, severe back pain or a noticeable loss of height — possible new spine fracture.
Symptoms of low calcium after starting denosumab or a strong medicine: numbness/tingling around the mouth or in the hands/feet, or muscle cramps/spasms.
You’re going to miss or delay a denosumab dose for any reason — call before the dose is late.

How can I best prevent falls at home and outside?
Can I get a home-safety evaluation or a referral to physical therapy or a fall-prevention program?
Are any of my medicines making me more likely to fall?
What activities are safe for me, and which should I avoid?
If I’ve already fractured, what’s our plan to prevent the next one — and how soon do we start?

Caregiver note. Do a slow walk-through of the home looking for trip hazards and dim spots; arrange grab bars and better lighting. Help schedule a vision check and pick out non-slip footwear. Encourage the strength-and-balance routine — doing it together helps consistency. And keep watch for the red flags above.

Support & Resources

This final section gathers the practical extras: a dedicated caregiver guide, how to find clinical trials, an honest look at treatments that don’t work, where to get expert care (with a focus on Utah and the Mountain West), how access differs around the world, a plain-language glossary, and the key sources behind this guide.

Caregiver Guide & Notes

Caregivers make osteoporosis treatment work in real life — because it is long-term, usually symptom-free, and full of small routines that are easy to let slide. Here is a focused playbook.

Oral bisphosphonates (weekly/monthly pills): first thing in the morning, on an empty stomach, with a full glass of plain water; stay upright (sitting or standing) and take nothing else by mouth for 30–60 minutes. Pick a consistent day; a phone alarm or pill organizer helps.
Zoledronic acid (yearly infusion): help schedule it and arrange a ride; expect possible flu-like symptoms for a day or two after the first infusion (acetaminophen and fluids help). Make sure vitamin D and calcium are adequate beforehand.
Denosumab (every 6 months): treat the calendar as sacred. Book the next injection before leaving the clinic; set reminders weeks ahead. If a dose might be missed or the medicine stopped, call the clinic before it’s late to arrange a follow-on medicine.
Daily anabolic injections (teriparatide, abaloparatide): support a steady daily routine and correct pen technique; store as directed (often refrigerated). Rotate injection sites; a checklist on the fridge helps.
Romosozumab (monthly, two shots): keep monthly appointments; the course is time-limited and must be followed by a preserver.

Never let denosumab be stopped or delayed without a follow-on medicine. If you remember one thing as a caregiver, make it this.
Always follow a bone-builder with a bone-preserver — confirm the next step is scheduled.
Support calcium (from food) and vitamin D every day.
Help with weight-bearing and balance exercise — ideally together.
Make the home safer (trip hazards, lighting, grab bars) and review sedating medicines with the clinician.
Arrange vision checks and good footwear.
Attend appointments and DXA scans; keep the records.
Watch for new thigh/groin pain, a non-healing jaw sore, sudden back pain or height loss, and signs of low calcium — and report them.
Offer encouragement through long, often invisible treatment. Progress here looks like “nothing happened” — which is exactly the goal.

>Clinical Trials

Research keeps improving osteoporosis care, and joining a trial is a reasonable option to discuss — especially if standard treatment isn’t enough or isn’t accessible. Trials drive progress everywhere in the world, so asking about them is reasonable in any region.

An honest note on trial listings. Which trials are recruiting changes week to week, so this guide does not print a list of “open” studies that would quickly go stale. Instead, search live (below). The trial IDs we do name elsewhere in this guide are the landmark completed studies that established today’s treatments — useful background you can read about, but not enrollment opportunities.

Go to ClinicalTrials.gov and search osteoporosis (add terms like postmenopausal, male, glucocorticoid, or a drug name).
Filter by Recruiting status and by your location (e.g., Utah) to find studies near you.
Read the eligibility criteria, then bring the study’s NCT number to your doctor to discuss fit and safety.
Ask your endocrinologist or a university bone-health center whether they run osteoporosis studies — academic centers often do.
Patient organizations (below) sometimes maintain trial-matching tools and plain-language summaries.

The landmark completed trials referenced in this guide — for example FREEDOM (denosumab; NCT00089791), HORIZON-PFT (zoledronic acid; NCT00049829), FRAME and ARCH (romosozumab; NCT01575834, NCT01631214), ACTIVE (abaloparatide; NCT01343004), and VERO (teriparatide vs risedronate; NCT01709110) — are searchable on ClinicalTrials.gov if you’d like to read what the evidence was built on.

Treatments That Have Not Worked (and Claims to Be Skeptical Of)

Online you’ll meet many bone “cures.” Honesty about what rigorous testing has not supported protects you from wasting money — or, worse, replacing real treatment with something that doesn’t prevent fractures.

Supplements alone for high-risk people. Calcium and vitamin D are a foundation, but by themselves they do not prevent fractures in people who need medication. Strontium, “bone-building” herbal blends, megadose vitamins, and similar products are not substitutes for proven medicines, and some carry their own risks.
Sodium fluoride. An older idea that increased bone density on paper but produced abnormal, more fragile bone — it did not reliably reduce fractures and is not used for this purpose.
Calcitonin (nasal spray). Largely fallen out of favor for osteoporosis because of weak fracture benefit and a possible small cancer signal with long-term use; other medicines are far better.
Whole-body vibration plates and similar devices: marketed widely, but evidence that they prevent fractures is weak. They are not a replacement for proven therapy.
Very high-dose vitamin D “boluses.” Occasional huge annual doses have not improved outcomes and, in some studies, were associated with more falls or fractures. Steady, appropriate dosing is the goal.
“Bone detox,” alkaline diets, and miracle cures. No rigorous evidence supports these for preventing fractures.

Bottom line: by all means eat well, move, and get sensible amounts of calcium and vitamin D — but if you are at real fracture risk, don’t let an unproven product stand in for a medicine that has been shown to keep you from breaking a hip or spine.

A note on supplements & interactions. Tell your clinician and pharmacist about every supplement and herbal product you take. Some interfere with absorption (for example, calcium taken at the same time as certain medicines), and others can interact with prescriptions. “Natural” does not mean “no interactions,” and no supplement is a substitute for standard care.

Where to Get Expert Care — Specialty Center Directory

Osteoporosis is usually managed by primary care, endocrinology, rheumatology, or a dedicated bone-health/fracture-liaison service. Below are starting points, with a focus on Utah and the Mountain West. Please verify current phone numbers and services when you call, as these can change.

Mountain West & Utah

University of Utah Health — Endocrinology / Osteoporosis & Metabolic Bone Disease (Salt Lake City). DXA scanning and vertebral fracture assessment, fracture-risk assessment, secondary-cause workup, and the full range of antiresorptive and anabolic therapy including infusions and injections. Main scheduling: 801-581-2897 (University of Utah Health general). Ask specifically for the bone-health/endocrinology clinic.
Intermountain Health — endocrinology and osteoporosis clinics & infusion centers (Wasatch Front and across Utah). Bone-density testing, zoledronic acid infusions, denosumab and anabolic therapy, and fracture-liaison services. Call the main Intermountain line, 801-442-2000, or your local Intermountain facility, for referrals.
George E. Wahlen VA Medical Center (Salt Lake City). Osteoporosis screening and treatment for veterans, including male osteoporosis. Main: 801-582-1565. (See Veterans note below.)
Orthopedic fracture-liaison services & infusion centers (University of Utah, Intermountain). Secondary fracture prevention after a broken bone, infusion/injection administration, and help coordinating specialty-drug approvals and patient-assistance programs.
Physical therapy, fall-prevention programs, and smoking-cessation help. Balance and strength training, home-safety evaluation, and the Utah Tobacco Quit Line: 1-800-QUIT-NOW.

US National Centers of Excellence

Many major academic medical centers have dedicated metabolic bone disease or osteoporosis programs — for example, leading university endocrinology and rheumatology departments and large multispecialty clinics across the country. To find one near you, ask your physician for a referral to a “metabolic bone disease” or “osteoporosis” clinic, or use the clinician-finder tools on the patient-organization websites listed below.

Veterans

The VA system screens and treats osteoporosis, including the often-overlooked osteoporosis in men. The George E. Wahlen VA Medical Center (Salt Lake City) serves the region. If a fracture or bone loss may be connected to military service or service-related medications, ask about service connection — it can affect coverage and care coordination. Veterans can also ask about VA fracture-prevention and fall-prevention programs.

Canada

Care is delivered through provincial health systems and family physicians, with specialist bone-health and fracture-liaison programs at academic centers. Osteoporosis Canada maintains patient resources and a national clinical practice guideline. Drug coverage varies by province: bisphosphonates are widely covered and inexpensive, while access to the bone-builders (and to denosumab biosimilars) depends on provincial formularies and may require meeting specific risk criteria. Ask your provider about provincial coverage and special-authorization forms.

International

Major bone-health and endocrinology centers exist worldwide and follow broadly similar principles. The International Osteoporosis Foundation (IOF) lists national member societies that can point you to local expert care and to the relevant national guideline. (See the International Access section for how availability differs by country.)

International Access & Regulatory Landscape

The science is global, but availability, cost, and even the order in which medicines arrived differ by country.

Broadly agreed everywhere: use DXA and FRAX to assess risk; calcium and vitamin D as a foundation; bisphosphonates as common first-line therapy; and bone-builder-first treatment for very high risk.
Risk thresholds are country-specific. FRAX is tuned to each nation’s fracture and death data, so the same risk factors can yield different 10-year risks and different “treat or not” cut-offs (for example, the UK and Canada use their own tools and thresholds).
Some medicines arrived in a different order. Romosozumab (Evenity) was approved first in Japan (2019), then in the United States and Europe.
Biosimilars are widening access. Lower-cost biosimilar versions of denosumab reached the US market (with FDA approval in 2024) and other regions, and teriparatide biosimilars are available in several countries — uptake and price vary by health system.
Cost stratifies treatment. Bisphosphonates are inexpensive and remain the worldwide mainstay; the bone-builders are costly and reimbursement-dependent, so in many places very-high-risk patients still receive a bone-slowing medicine first simply because a bone-builder isn’t available or affordable.

Approval status (general): bisphosphonates, denosumab (plus biosimilars), teriparatide, abaloparatide, and romosozumab are approved across the major regulators (US FDA, European EMA, Japan’s PMDA, Health Canada, UK/NICE, China’s NMPA), though exact indications, age and risk criteria, and reimbursement differ. Always confirm what is available and covered where you live.

Glossary

Antiresorptive: a medicine that slows the loss of bone (bisphosphonates, denosumab, raloxifene).
Anabolic (bone-building): a medicine that builds new bone (teriparatide, abaloparatide, romosozumab).
Atypical femoral fracture (AFF): a rare, unusual break in the thigh bone linked to very long use of bone-slowing medicines; may be preceded by thigh/groin pain.
Bisphosphonate: the common first-line family of bone-slowing medicines (alendronate, risedronate, ibandronate, zoledronic acid).
Biosimilar: a lower-cost version of a biologic medicine (such as denosumab) that is highly similar, with no clinically meaningful differences, to the original.
Drug holiday: a planned pause in a bisphosphonate after several years, possible because the medicine lingers in bone.
DXA: the standard bone-density scan; gives your T-score.
Fragility fracture: a break from a fall from standing height or less — a warning sign of high future risk.
FRAX: an online calculator of your 10-year fracture risk.
Osteonecrosis of the jaw (ONJ): a rare area of jaw bone that doesn’t heal, usually after dental surgery.
Osteopenia (low bone mass): bone density below normal but not yet osteoporosis (T-score −1.0 to −2.5).
Rebound (after denosumab): the rapid bone loss and multiple spine fractures that can follow stopping denosumab without a follow-on medicine.
Secondary osteoporosis: bone loss driven by another condition or medicine (e.g., steroids, low hormones, celiac disease, overactive parathyroid).
Sequencing: the deliberate order of medicines — usually build first, then preserve.
SERM: a medicine like raloxifene that acts like estrogen in bone; reduces spine fractures.
T-score: your bone density compared with a healthy young adult; −2.5 or lower means osteoporosis.
Trabecular bone score (TBS): a measure of bone quality from the spine DXA image.
Vertebral fracture assessment (VFA): a spine image that finds fractures you may not feel.

Key References & Sources

This guide draws on major society guidelines and landmark clinical trials. Identifiers below are real and were checked against ClinicalTrials.gov and PubMed; your clinician can look up any of them.

Endocrine Society — Pharmacological Management of Osteoporosis in Postmenopausal Women (2019; 2020 update).
American Association of Clinical Endocrinology / American College of Endocrinology (AACE/ACE) — Postmenopausal Osteoporosis Guideline (2020).
Bone Health & Osteoporosis Foundation (BHOF, formerly NOF) — Clinician’s Guide to Prevention and Treatment of Osteoporosis.
American College of Physicians (ACP) — Pharmacologic Treatment of Primary Osteoporosis (2023).
American College of Rheumatology (ACR) — Glucocorticoid-Induced Osteoporosis Guideline.
International: NOGG (UK), ESCEO/IOF (Europe), Osteoporosis Canada (2023), Japan Osteoporosis Society; USPSTF screening recommendation; ISCD Official Positions on DXA.

FREEDOM — denosumab vs placebo. NCT00089791 (Cummings et al., N Engl J Med 2009;361:756–765). Extension: NCT00523341.
HORIZON-PFT — once-yearly zoledronic acid. NCT00049829 (Black et al., N Engl J Med 2007;356:1809–1822; PMID 17476007).
FRAME — romosozumab vs placebo. NCT01575834 (Cosman et al., N Engl J Med 2016;375:1532–1543).
ARCH — romosozumab then alendronate vs alendronate. NCT01631214 (Saag et al., N Engl J Med 2017;377:1417–1427; PMID 28892457).
BRIDGE — romosozumab in men. NCT02186171 (Lewiecki et al., J Clin Endocrinol Metab 2018).
ACTIVE — abaloparatide vs placebo vs teriparatide. NCT01343004 (Miller et al., JAMA 2016). Extension (ACTIVExtend): NCT01657162.
VERO — teriparatide vs risedronate. NCT01709110 (Kendler et al., Lancet 2017; PMID 29129436).
DATA / DATA-Switch — teriparatide/denosumab sequencing. NCT00926380 (Leder et al., Lancet 2015; PMID 26144908).
Teriparatide Fracture Prevention Trial — Neer et al., N Engl J Med 2001;344:1434–1441 (pre-registry era; no NCT).
FLEX (alendronate holiday) — Black et al., JAMA 2006;296:2927–2938 (pre-registry era).

Patient Organizations & Tools

Bone Health & Osteoporosis Foundation — bonehealthandosteoporosis.org (education, support, medication-assistance information).
National Osteoporosis Foundation patient resources.
American Bone Health — fracture-risk tools and education.
International Osteoporosis Foundation (IOF) — national societies and global resources.
ClinicalTrials.gov — clinical-trial listings.
Osteoporosis Canada — Canadian guideline and patient resources.

Important disclaimer. This guide is for education and to help you prepare for conversations with your healthcare team. It is not medical advice, a diagnosis, or a treatment recommendation, and it cannot account for your individual situation. Medicines, evidence, and approvals evolve; details here may become out of date. Always follow the advice of your own qualified clinicians, and seek prompt care for the red flags described above. The center listings and phone numbers are starting points that may change — please verify before relying on them.